🔗 Share this article

As America undertakes historic changes to its immunization schedules, an unexpected name has emerged somewhat surprisingly: Høeg, a Danish American physician and public health researcher who rose to prominence by casting doubt on COVID-19 shots in the pandemic and has zeroed in on alleged fatalities after Covid immunization in her recent time at the Food and Drug Administration.

Planned Changes to Pediatric Immunization Schedule

Public health authorities had intended to reveal radical revisions to the pediatric vaccination calendar in December, bringing the US with the Danish national calendar, it is understood – a major change that would put the US at odds with a large portion of the global community with little proof for improved outcomes. The announcement has been postponed until the coming year.

Instead of the director of the vaccine center, Dr. Høeg is listed to address the audience at the event. She was newly appointed temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth appointee to run the center this year.

A New Direction at the Agency

The acting appointment could signify a closer partnership between the drug and vaccine branches as Dr. Høeg and Prasad consolidate power at the agency – and it suggests a increased emphasis upon dismantling long-standing vaccines at the FDA.

Høeg has repeatedly called for ending some pediatric vaccine recommendations in the US to become more in line with Denmark's approach, a country with comprehensive healthcare and a population approximately the population of Wisconsin’s.

In her initial comments, she has persisted in emphasizing on immunizations – usually the domain of Prasad, chief of the FDA’s CBER – instead of medication approval.

Questions Over Background

Dr. Høeg has no apparent background in medication creation, regulation or administrative roles, which has been standard for former directors of the Center for Biologics Evaluation and Research. She has been employed at the FDA as a senior adviser to the commissioner and CBER since earlier this year.

“She appears not to have any of the qualifications” for running the pharmaceutical oversight division, remarked Dr. Jonathan Howard. “She lacks experience running a randomized controlled trial. She is not versed in running a large organization. She has no expertise in drug approvals.”

Former heads of CBER would “understand legal statutes and the research of pharmaceutical innovation”, said Dr. Janet Woodcock. “Frankly, she doesn’t have the type of experience that prior appointees who headed CBER have had.”

This division has an enormous workload at the agency, she emphasized.

“Everybody just pays attention on the new drug program, but the off-patent medication office authorizes a multitude of generic drugs. There is also a biosimilars division, over-the-counter program and so forth, and each of these must be managed,” Woodcock explained. “The responsibility you overlook, that is the part that I always told people is going to cause problems.”

Furthermore, a significant administrative component to the job, which supervises over 5,000 staff members. “It’s a enormous management job, if you execute it properly,” she added.

Agency Reaction and Controversial Programs

Regarding concerns about Dr. Høeg's fitness for the role and whether this appointment represents greater collaboration among agency officials on immunizations, a representative said that the “concerns rely on inaccurate presumptions”.

“Her experience matches the functions of her role,” the spokesperson explained, citing the time Høeg spent advising the agency head on “drug safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As acting director, Høeg inherits the agency head's controversial expedited review system, a controversial rapid therapy clearance system that allegedly worried her former heads. “By what process are these therapies being selected for this expedited pathway? Who makes the calls?” Dr. Howard said. “There’s a lot of secrecy happening at the agency right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards laxer rules of most medications, aside from vaccines.”

Documented History on Immunizations

Concerning immunizations, Høeg has a clearer, if concerning, history, critics said. She authored a study using unconfirmed public submissions to assess the rate of myocarditis following Covid vaccination. She counseled the state of Florida chief medical officer Joseph Ladapo, who reportedly have altered data to indicate Covid vaccines are more dangerous than they are.

Part of her “policy goals” for the current administration featured altering regulations for new vaccines and halting “unnecessary” immunizations, she remarked post-election on a audio program. At the agency, Høeg has allegedly proposed barring adolescent males from receiving COVID-19 vaccinations.

“She is an all-around true believer who begins with her beliefs and tailors the evidence to fit the data in a very misleading, untruthful manner,” Howard argued.

Taking Control and a “Campaign of Retribution”

Dr. Høeg became part of other contrarians, {like|